logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Bryan B Molloy

USPTO Granted Patents = 25

Average Co-Inventor Count = 1.5

ph-index = 12

Forward Citations = 494(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1976 - 1982)
  • North Salem, IN (US) (1980 - 1986)

Company Filing History:

goldMedal25 out of 4,449 
 
Eli Lilly and Company
 patents

Years Active: 1976-1986

Loading Chart...
25 patents (USPTO):Explore Patents
1. 4626549 - Treatment of obesity with aryloxyphenylpropylamines (1986-12-02),
2. 4596827 - Alkylsulfonamidophenylalkylamine compounds used for treating arrhythmia (1986-06-24),
3. 4584404 - Substituted phenoxyphenylproply dimethylamines (1986-04-22),
4. 4569801 - Alkylsulfonamidophenylalkylamines (1986-02-11),
5. 4528177 - Imaging agents and method (1985-07-09),
6. 4395410 - Quaternary ammonium antiarrhythmic drugs (1983-07-26),
7. 4336269 - Para-nitrophenylalkylamines (1982-06-22),
8. 4314081 - Arloxyphenylpropylamines (1982-02-02),
9. 4313896 - Aryloxyphenylpropylamines (1982-02-02),
10. 4289787 - Quaternary ammonium antiarrhythmic drugs (1981-09-15),
11. 4277501 - Para-nitrophenylalkylamines and pharmaceutical compositions (1981-07-07),
12. 4259354 - Method of treating arrhythmia (1981-03-31),
13. 4207343 - 1-Phenyl-3-(substituted phenoxy)propylamines (1980-06-10),
14. 4194009 - Aryloxyphenylpropylamines for obtaining a psychotropic effect (1980-03-18),
15. 4168388 - Trifluoromethylphenyl benzyl ethers (1979-09-18),

Title: Innovator Spotlight: Bryan B. Molloy

Introduction: Bryan B. Molloy is an accomplished inventor based in Indianapolis, Indiana, with a remarkable portfolio of 25 patents. His innovative contributions primarily focus on pharmaceuticals and therapeutic agents, aiming to enhance health outcomes and address various medical conditions.

Latest Patents: Among his latest patents, Molloy developed a treatment for obesity utilizing aryloxyphenylpropylamines. This invention highlights 3-Aryloxy-3-phenylpropylamines and their acid addition salts, which effectively block the uptake of monoamines by brain neurons. This mechanism proves beneficial in treating several disorders, including issues related to sleep, sexual performance, appetite, muscular function, and pituitary function. Another significant innovation from Molloy is the alkylsulfonamidophenylalkylamine compounds, aimed at treating arrhythmia. This new class of compounds presents potent antiarrhythmic properties while also showing good oral bioavailability, making them a promising option in cardiovascular treatments.

Career Highlights: Bryan currently works at Eli Lilly and Company, a leading global pharmaceutical company dedicated to creating medicines that help people live longer, healthier lives. His extensive work in the field of pharmaceuticals has solidified his position as a key inventor within the company.

Collaborations: Throughout his career, Molloy has collaborated with notable colleagues such as Mitchell I. Steinberg and Klaus K. Schmiegel. These partnerships have fostered an innovative environment, allowing for the exchange of ideas and expertise, ultimately leading to groundbreaking advancements in drug development.

Conclusion: Bryan B. Molloy's contributions to the field of pharmaceuticals exemplify the power of innovation in medicine. His cutting-edge patents not only advance therapeutic options but also improve the quality of life for countless individuals experiencing complex health challenges. As he continues to innovate at Eli Lilly and Company, Molloy's work remains vital in shaping the future of medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…